Reviva Pharmaceuticals (RVPH) cuts Q2 loss as it targets 2046 brilaroxazine patent life
Rhea-AI Filing Summary
Reviva Pharmaceuticals Holdings, Inc. reported second quarter 2026 results and outlined key milestones for its lead drug candidate brilaroxazine. A U.S. composition of matter patent application for a new form of brilaroxazine is seeking accelerated review, which the company believes could extend patent life and commercial exclusivity through 2046. FDA feedback on use of the new formulation in the RECOVER-2 registrational Phase 3 schizophrenia trial and in a planned New Drug Application is expected in the fourth quarter of 2026, with a bioequivalence study planned for the same period and RECOVER-2 patient enrollment targeted for the first half of 2027, subject to additional financing.
Cash and cash equivalents were $19.9 million as of June 30, 2026, up from $14.4 million at December 31, 2025, with total assets of $21.1 million and total liabilities of $5.9 million. For the quarter, operating expenses fell to $2.6 million from $6.1 million a year earlier, and net loss narrowed to $2.45 million (or $0.19 per share) from $6.05 million (or $2.40 per share). Stockholders’ equity increased to $15.2 million, while accumulated deficit reached $189.8 million. The company’s common stock now trades on the OTCQB Venture Market under the symbol RVPH.
Positive
- Net loss significantly narrowed in Q2 2026 to $2.45 million from $6.05 million a year earlier, driven by lower research and development and general and administrative expenses.
- Cash and equity positions strengthened, with cash rising to $19.9 million from $14.4 million and stockholders’ equity increasing to $15.2 million from $8.6 million since December 31, 2025.
Negative
- Company remains loss-making, posting a Q2 2026 net loss of $2.45 million and an accumulated deficit of $189.8 million as of June 30, 2026.
- Shares trade on the OTCQB Venture Market following suspension and removal from Nasdaq, which the company notes can involve limited liquidity, increased volatility, sporadic trading, and potential adverse impact on capital-raising.
Filing Explained
The June 30 balance sheet reports
8-K Event Classification
3 items: 2.02, 7.01, 9.01
3 items
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Cash and cash equivalents: $19,889,960
Total assets: $21,140,590
Total liabilities: $5,933,345
+5 more
8 metrics
Cash and cash equivalents
$19,889,960
As of June 30, 2026
Total assets
$21,140,590
As of June 30, 2026
Total liabilities
$5,933,345
As of June 30, 2026
Net loss Q2 2026
$2,447,831
Three months ended June 30, 2026
Net loss Q2 2025
$6,053,610
Three months ended June 30, 2025
Research and development expense
$1,394,569
Three months ended June 30, 2026
Accumulated deficit
$189,781,770
As of June 30, 2026
Shares outstanding
13,110,377
Common stock issued and outstanding as of June 30, 2026
Key Terms
composition of matter patent, New Drug Application (NDA), bioequivalence study, registrational Phase 3 trial, +2 more
6 terms
composition of matter patent regulatory
"U.S. composition of matter patent application filed seeking accelerated review"
A composition of matter patent is a legal right that protects a specific chemical, molecule, material or formulated mixture—think of it as locking down a unique recipe for a substance. For investors it matters because the patent can give a company exclusive control to make, sell, or license that substance, creating a potential source of revenue and a competitive barrier similar to owning the only map to a valuable resource.
New Drug Application (NDA) regulatory
"planned New Drug Application (NDA) submission for brilaroxazine for the treatment"
A new drug application (NDA) is a formal request submitted to regulatory authorities to gain approval for a new medication to be sold and used by the public. It is a comprehensive review process that examines the drug’s safety, effectiveness, and manufacturing quality. For investors, an NDA approval can signal a potential breakthrough product and influence a company's stock value.
bioequivalence study medical
"plan to initiate a bioequivalence study to confirm comparability of the new formulation"
A bioequivalence study tests whether a new version of a drug—often a generic or alternate formulation—delivers the same amount of active ingredient into the bloodstream at the same speed as a reference product. Think of it like checking that a copy of a key opens the lock as reliably as the original. For investors, successful bioequivalence means a cheaper, faster regulatory route to market, potential revenue from competition or substitution, and lower scientific risk compared with entirely new drugs.
registrational Phase 3 trial medical
"RECOVER-2 registrational Phase 3 trial expected to initiate in 1H 2027"
A registrational phase 3 trial is the late-stage clinical study intended to generate the clear safety and effectiveness data that health regulators require to decide whether to approve a new drug or medical device. These studies typically involve larger patient groups and directly compare the new treatment to existing care so regulators can judge real-world benefit and risks. For investors, a successful registrational trial can unlock market access and long-term revenue like passing a final exam, while failure can sharply reduce a company’s valuation and alter its financial outlook.
OTCQB Venture Market financial
"common stock is currently quoted on the OTCQB Venture Market operated"
The OTCQB Venture Market is a tier of the over‑the‑counter (OTC) trading platform that groups early‑stage, smaller companies that do not meet the stricter requirements of higher OTC tiers. It gives investors a way to buy and sell shares in these higher‑risk, less mature firms with generally lower reporting and transparency standards; think of it as a marketplace’s “starter lane” where potential is available but uncertainty and volatility are higher, so investors should expect greater risk and do extra homework.
accumulated deficit financial
"Accumulated deficit | | | (189,781,770 | )"
Accumulated deficit is the running total of a company’s past net losses minus any profits, showing how much the business has eaten into its own funds over time—think of it like a bank account that’s been overdrawn by repeated shortfalls. It matters to investors because a large accumulated deficit reduces the cushion that protects owners and creditors, can limit dividends or borrowing, and signals how much funding the company may need to reach profitability.
Earnings Snapshot
Net loss: $2,447,831 for Q2 2026
Quarter and six months ended June 30, 2026
Net loss
$2,447,831 for Q2 2026
Lower than $6,053,610 in Q2 2025
Operating expenses
$2,617,543 for Q2 2026
Lower than $6,072,982 in Q2 2025
Cash and cash equivalents
$19,889,960 as of June 30, 2026
Higher than $14,438,792 as of December 31, 2025
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What were Reviva Pharmaceuticals (RVPH) key Q2 2026 financial results?
Reviva reported a Q2 2026 net loss of $2.45 million, or $0.19 per share, compared with a net loss of $6.05 million, or $2.40 per share, in Q2 2025. Operating expenses declined to $2.62 million from $6.07 million.
How much cash does Reviva Pharmaceuticals (RVPH) have as of June 30, 2026?
As of June 30, 2026, Reviva held $19.9 million in cash and cash equivalents, up from $14.4 million at December 31, 2025. Total assets were $21.1 million and total liabilities were $5.9 million.
What is the status of Reviva’s brilaroxazine patent and exclusivity?
Reviva has filed a U.S. composition of matter patent application for a new form of brilaroxazine and is seeking accelerated review. The company believes this could extend patent life and commercial exclusivity for brilaroxazine through 2046.
What upcoming clinical milestones did Reviva Pharmaceuticals (RVPH) outline for brilaroxazine?
Reviva expects FDA feedback in Q4 2026 on using a new brilaroxazine formulation in the RECOVER-2 Phase 3 trial and NDA. It plans a bioequivalence study in Q4 2026 and targets RECOVER-2 patient enrollment in 1H 2027, subject to additional financing.
On which market is Reviva Pharmaceuticals (RVPH) currently quoted?
Reviva’s common stock is quoted on the OTCQB Venture Market under the symbol RVPH. The company notes risks versus a national exchange, including limited liquidity, higher volatility, sporadic trading, and potential challenges raising additional capital.
How did Reviva Pharmaceuticals (RVPH) operating expenses change year over year in Q2 2026?
Total operating expenses in Q2 2026 were $2.62 million, down from $6.07 million in Q2 2025. Research and development declined to $1.39 million from $3.72 million, and general and administrative expenses fell to $1.22 million from $2.35 million.